Shattuck Labs (STTK) Price Target Raised by 33.33% to $4.08
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2025
0mins
Should l Buy STTK?
Source: NASDAQ.COM
Price Target Update: The average one-year price target for Shattuck Labs (NasdaqGS:STTK) has been revised to $4.08 per share, reflecting a 33.33% increase from the previous estimate of $3.06.
Fund Sentiment: There are currently 101 funds reporting positions in Shattuck Labs, a decrease of 34 funds (25.19%) from the last quarter, while the average portfolio weight dedicated to STTK has increased by 221.31%.
Shareholder Activity: Notable shareholders include Orbimed Advisors and Adage Capital Partners, both holding 6,306K shares (9.97% ownership), with Adage increasing its stake by 25.87% over the last quarter.
Options Sentiment: The put/call ratio for STTK is 0.04, indicating a bullish outlook among investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STTK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STTK
Wall Street analysts forecast STTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STTK is 5.00 USD with a low forecast of 4.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 3.570
Low
4.00
Averages
5.00
High
6.00
Current: 3.570
Low
4.00
Averages
5.00
High
6.00
About STTK
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Shattuck Labs to Participate in Immunology Symposium
- Conference Participation: Shattuck Labs will participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026, showcasing its latest advancements in treating inflammatory and immune-mediated diseases, which is expected to attract attention from investors and industry experts.
- Executive Presentation: CEO Dr. Taylor Schreiber, CFO Andrew R. Neill, and VP of Clinical Development Michael Choi will jointly participate in the discussion, sharing Shattuck's strategic vision in developing novel therapeutic solutions, thereby enhancing the company's visibility in the biotechnology sector.
- SL-325 Development Progress: Shattuck's SL-325, a potential first-in-class DR3 blocking antibody, has demonstrated a favorable safety profile in non-human primates and is currently undergoing Phase 1 clinical trials, which, if successful, could provide new treatment options for inflammatory bowel disease and other conditions, representing significant market potential.
- Technical Advantages: SL-325 has shown superior activity over TL1A antibodies in preclinical studies, indicating its potential advantages in TNF receptor-targeted therapies, further solidifying Shattuck's technological leadership in the biopharmaceutical field.
See More
Shattuck Labs Shares Rise After Piper Sandler Initiates Overweight Rating
- Rating Upgrade: Piper Sandler initiates coverage on Shattuck Labs (STTK) with an Overweight rating and a $15 price target, likely driving an increase in the company's stock price.
- Clinical Trial Catalysts: Analyst Yasmeen Rahimi highlights that Shattuck's lead candidate SL-325 is set to report initial Phase 1 trial results in Q2 and initiate mid-stage trials in Q3, presenting significant market opportunities for the company.
- Mechanism Validation: The mechanism of action for SL-325 has been validated by nearly eight drugs targeting TL1A, a protein that causes inflammation through interaction with the DR3 receptor, which Shattuck's candidate aims to block, providing durable inflammation protection.
- Differentiated Treatment: The analyst notes that SL-325 offers a differentiated approach to treating inflammatory bowel disease patients, expected to have a greater inhibitory effect, thereby enhancing its competitive position in the market.
See More
Latest Rating Changes on Wall Street
- Mizuho Upgrades Applied Materials: Mizuho upgrades Applied Materials (AMAT) to Outperform from Neutral, raising the price target to $370, reflecting confidence in the semiconductor company's accelerating growth, which is expected to boost its stock price.
- Jefferies Downgrades BJ's Wholesale: Jefferies downgrades BJ's Wholesale from Buy to Hold, citing slower growth and increased risks in competitive markets, which may lead to underperformance and affect investor sentiment.
- Morgan Stanley Upgrades Johnson & Johnson: Morgan Stanley upgrades Johnson & Johnson (JNJ) to Overweight with a price target increase to $252, based on expectations of new product contributions and a higher P/E ratio, likely driving future earnings growth.
- Barclays Initiates TPG as Overweight: Barclays initiates TPG with an Overweight rating, highlighting its strong positioning for medium-term growth in a recovering capital markets environment, which is expected to attract more investor interest.
See More
Shattuck Labs (STTK) Stock Soars 74% Following Analyst Upgrade to Buy
- Analyst Upgrade: On December 1, H.C. Wainwright's Joseph Pantginis upgraded Shattuck Labs from neutral to buy with a price target of $6 per share, nearly triple its previous level, resulting in a nearly 74% surge in stock price.
- Drug Potential: Pantginis highlighted that SL-325, an investigational drug targeting inflammatory and immune-mediated disorders, is currently in clinical trials for irritable bowel syndrome (IBS) and has potential efficacy for multiple indications.
- Funding Support: In August, Shattuck closed a private funding round raising up to $103 million, which is expected to fund operations through 2029, providing crucial financial backing for its clinical-stage development.
- Financial Improvement: In Q3, Shattuck reduced its net loss to just over $10 million from nearly $17 million in the same period of 2024, while general and administrative expenses fell by 11% year-over-year, indicating improved financial discipline within the company.
See More
Shattuck Labs Upgraded to Buy by Analyst, Stock Surges 74%
- Analyst Upgrade: Joseph Pantginis from H.C. Wainwright upgraded Shattuck Labs to a buy rating on December 1, setting a price target of $6 per share, which catalyzed a nearly 74% surge in the stock price during December 2025, reflecting strong market confidence in the company.
- Drug Development Progress: Pantginis's positive outlook is largely based on SL-325, a first-in-class antibody drug targeting inflammatory and immune-mediated disorders, currently being evaluated for irritable bowel syndrome (IBS), with potential efficacy for multiple indications, heightening market expectations.
- Enhanced Funding Support: In August, Shattuck closed a private funding round raising up to $103 million, which is expected to fund operations through 2029, alleviating common financing concerns for clinical-stage biotech firms and bolstering investor confidence.
- Improved Financial Performance: In Q3, Shattuck reduced its net loss to just over $10 million under GAAP, down from nearly $17 million in the same period of 2024, while general and administrative expenses fell by 11% year-over-year, indicating progress in cost management efforts.
See More
Shattuck Labs Upgraded to Buy by Analyst, Stock Soars 74%
- Analyst Upgrade: Joseph Pantginis from H.C. Wainwright upgraded Shattuck Labs to a buy rating on December 1, setting a price target of $6 per share, which led to a nearly 74% increase in stock price in December, significantly boosting investor confidence.
- Drug Development Progress: SL-325, a first-in-class antibody targeting inflammatory and immune-mediated disorders, is currently undergoing clinical trials, with the FDA approving its IND application in August, indicating the company's potential in drug development and market prospects.
- Funding Support: In August, Shattuck closed a private funding round, raising up to $103 million, which will support its operations through 2029, alleviating the financing pressures typically faced by clinical-stage biotech firms.
- Improved Financials: The company reported a narrowed net loss of just over $10 million in Q3, down from nearly $17 million in the same period of 2024, while general and administrative expenses fell by 11% year-over-year, demonstrating progress in cost management.
See More
Shattuck Labs to Participate in Immunology Symposium
- Conference Participation: Shattuck Labs will participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026, showcasing its latest advancements in treating inflammatory and immune-mediated diseases, which is expected to attract attention from investors and industry experts.
- Executive Presentation: CEO Dr. Taylor Schreiber, CFO Andrew R. Neill, and VP of Clinical Development Michael Choi will jointly participate in the discussion, sharing Shattuck's strategic vision in developing novel therapeutic solutions, thereby enhancing the company's visibility in the biotechnology sector.
- SL-325 Development Progress: Shattuck's SL-325, a potential first-in-class DR3 blocking antibody, has demonstrated a favorable safety profile in non-human primates and is currently undergoing Phase 1 clinical trials, which, if successful, could provide new treatment options for inflammatory bowel disease and other conditions, representing significant market potential.
- Technical Advantages: SL-325 has shown superior activity over TL1A antibodies in preclinical studies, indicating its potential advantages in TNF receptor-targeted therapies, further solidifying Shattuck's technological leadership in the biopharmaceutical field.
See More
Shattuck Labs Shares Rise After Piper Sandler Initiates Overweight Rating
- Rating Upgrade: Piper Sandler initiates coverage on Shattuck Labs (STTK) with an Overweight rating and a $15 price target, likely driving an increase in the company's stock price.
- Clinical Trial Catalysts: Analyst Yasmeen Rahimi highlights that Shattuck's lead candidate SL-325 is set to report initial Phase 1 trial results in Q2 and initiate mid-stage trials in Q3, presenting significant market opportunities for the company.
- Mechanism Validation: The mechanism of action for SL-325 has been validated by nearly eight drugs targeting TL1A, a protein that causes inflammation through interaction with the DR3 receptor, which Shattuck's candidate aims to block, providing durable inflammation protection.
- Differentiated Treatment: The analyst notes that SL-325 offers a differentiated approach to treating inflammatory bowel disease patients, expected to have a greater inhibitory effect, thereby enhancing its competitive position in the market.
See More
Latest Rating Changes on Wall Street
- Mizuho Upgrades Applied Materials: Mizuho upgrades Applied Materials (AMAT) to Outperform from Neutral, raising the price target to $370, reflecting confidence in the semiconductor company's accelerating growth, which is expected to boost its stock price.
- Jefferies Downgrades BJ's Wholesale: Jefferies downgrades BJ's Wholesale from Buy to Hold, citing slower growth and increased risks in competitive markets, which may lead to underperformance and affect investor sentiment.
- Morgan Stanley Upgrades Johnson & Johnson: Morgan Stanley upgrades Johnson & Johnson (JNJ) to Overweight with a price target increase to $252, based on expectations of new product contributions and a higher P/E ratio, likely driving future earnings growth.
- Barclays Initiates TPG as Overweight: Barclays initiates TPG with an Overweight rating, highlighting its strong positioning for medium-term growth in a recovering capital markets environment, which is expected to attract more investor interest.
See More
Shattuck Labs (STTK) Stock Soars 74% Following Analyst Upgrade to Buy
- Analyst Upgrade: On December 1, H.C. Wainwright's Joseph Pantginis upgraded Shattuck Labs from neutral to buy with a price target of $6 per share, nearly triple its previous level, resulting in a nearly 74% surge in stock price.
- Drug Potential: Pantginis highlighted that SL-325, an investigational drug targeting inflammatory and immune-mediated disorders, is currently in clinical trials for irritable bowel syndrome (IBS) and has potential efficacy for multiple indications.
- Funding Support: In August, Shattuck closed a private funding round raising up to $103 million, which is expected to fund operations through 2029, providing crucial financial backing for its clinical-stage development.
- Financial Improvement: In Q3, Shattuck reduced its net loss to just over $10 million from nearly $17 million in the same period of 2024, while general and administrative expenses fell by 11% year-over-year, indicating improved financial discipline within the company.
See More
Shattuck Labs Upgraded to Buy by Analyst, Stock Surges 74%
- Analyst Upgrade: Joseph Pantginis from H.C. Wainwright upgraded Shattuck Labs to a buy rating on December 1, setting a price target of $6 per share, which catalyzed a nearly 74% surge in the stock price during December 2025, reflecting strong market confidence in the company.
- Drug Development Progress: Pantginis's positive outlook is largely based on SL-325, a first-in-class antibody drug targeting inflammatory and immune-mediated disorders, currently being evaluated for irritable bowel syndrome (IBS), with potential efficacy for multiple indications, heightening market expectations.
- Enhanced Funding Support: In August, Shattuck closed a private funding round raising up to $103 million, which is expected to fund operations through 2029, alleviating common financing concerns for clinical-stage biotech firms and bolstering investor confidence.
- Improved Financial Performance: In Q3, Shattuck reduced its net loss to just over $10 million under GAAP, down from nearly $17 million in the same period of 2024, while general and administrative expenses fell by 11% year-over-year, indicating progress in cost management efforts.
See More
Shattuck Labs Upgraded to Buy by Analyst, Stock Soars 74%
- Analyst Upgrade: Joseph Pantginis from H.C. Wainwright upgraded Shattuck Labs to a buy rating on December 1, setting a price target of $6 per share, which led to a nearly 74% increase in stock price in December, significantly boosting investor confidence.
- Drug Development Progress: SL-325, a first-in-class antibody targeting inflammatory and immune-mediated disorders, is currently undergoing clinical trials, with the FDA approving its IND application in August, indicating the company's potential in drug development and market prospects.
- Funding Support: In August, Shattuck closed a private funding round, raising up to $103 million, which will support its operations through 2029, alleviating the financing pressures typically faced by clinical-stage biotech firms.
- Improved Financials: The company reported a narrowed net loss of just over $10 million in Q3, down from nearly $17 million in the same period of 2024, while general and administrative expenses fell by 11% year-over-year, demonstrating progress in cost management.
See More
